CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology, which has been validated in a number of animal models including non-human primates, will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
**Our vision** is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria, and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases.
The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents. CaroGen, founded in 2012 and headquartered in the United States, received a $6.80M grant investment on 12 December 2023 from the U.S. Department of Defense. This innovative biopharmaceutical company aims to revolutionize vaccine development and make a significant impact in controlling and preventing infectious diseases globally.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $6.80M | 1 | U.S. Department of Defense | 12 Dec 2023 |
| Grant | $3.00M | 1 | National Institutes of Health | 03 May 2021 |
| Grant | $1.40M | 1 | National Institutes of Health | 27 Mar 2019 |
| Seed Round | $150.00K | 1 |
|
08 Sep 2013 |
No recent news or press coverage available for CaroGen Corporation.
We care about your data, and we'd love to use cookies make your experience better.
